Lexaria Bioscience Corp. 10-Q

Item 1A. Risk Factors Much of the information included in this quarterly report includes or is based upon estimates, projections or other "forward looking statements". Such forward looking statements include any projections or estimates made by us and our management in connection with our business operations. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. The risks associated with our business, common stock and other factors were with those described in the consolidated financial statements for the year ended August 31, 2020. Page 29 of 31 Table of Contents Item 6. Exhibits, Financial Statement Schedules 31.1 Section 302 Certifications under Sarbanes-Oxley Act of 2002 of Principal Executive Officer 31.2 Section 302 Certifications under Sarbanes-Oxley Act of 2002 of Principal Financial Officer and Principal Accounting Officer 32.1 Section 906 Certification under Sarbanes Oxley Act of 2002 of Principal Executive Officer 32.2 Section 906 Certification under Sarbanes Oxley Act of 2002 of Principal Financial Officer and Principal Accounting Officer (101)** Interactive Data Files 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document *Incorporated by reference to same exhibit filed with the Company's Registration Statement on Form SB-2 dated January 10, 2006. ** Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections. Page 30 of 31 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LEXARIA BIOSCIENCE CORP. By: /s/ Christopher Bunka Christopher Bunka Chief Executive Officer, Chairman and Director (Principal Executive Officer) Date: January 14, 2021 In accordance with the Exchange Act, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. By: /s/ Christopher Bunka Christopher Bunka Chief Executive Officer, Chairman and Director (Principal Executive Officer) Date: January 14, 2021 By: /s/ John Docherty John Docherty President and Director Date: January 14, 2021 By: /s/ Allan Spissinger Allan Spissinger CPA, CA Chief Financial Officer (Principal Financial and Accounting Officer) Date: January 14, 2021 Page 31 of 31